Abstract 278P
Background
Radiotherapy is an effective treatment option for local control of prostate cancer, but its role in the treatment of oligometastatic prostate cancer (omPCa) remains unclear. This study aimed to investigate the potential survival benefit of full-coverage radiotherapy in patients with omPCa.
Methods
A retrospective analysis was conducted on patients with omPCa who received full-coverage radiotherapy between July 2012 and June 2022. Full-coverage radiotherapy was defined as radiotherapy to all lesions, including the primary site and metastatic lesions. Overall survival (OS) was the primary endpoint, and biochemical progression-free survival (bPFS) and radiological progression-free survival (rPFS) were the secondary endpoint. The Kaplan-Meier method was used to estimate univariate analysis, and the log-rank test was used to conduct multivariate analysis.
Results
A total of 33 patients, including 31 de novo oligometastatic hormone-sensitive prostate cancer (omHSPC) patients and 2 oligometastatic castration-resistant prostate cancer (omCRPC) patients, were enrolled in the study. The median follow-up was 38.8 months (range: 4.2–70.6 months). The survival rates at 2, 3, and 5 years were 100%, 95.7%, and 81.2%, respectively. The median bPFS was 58.9 months (95% CI: 47.7 - 70.1 months). The median rPFS is 55.3 months (95% CI: 39.9 -70.8 months). According to the univariate analysis, TURP prior to radiotherapy, presence of symptoms related to the lesions, and the pre-radiotherapy status of CRPC were associated with poorer survival. Multivariate analysis showed EBRT synchronized with ADT or chemotherapy (p=0.016), non-CRPC status before radiotherapy(p=0.000), and PSA levels more than 1 ng/ml before radiotherapy ( p=0.014) may be associated with longer rPFS. Both univariate and multivariate studies have demonstrated that the coexistence of lymph node and bone metastases is associated with a higher risk of biochemical recurrence (p=0.02). The occurrence of acute adverse reactions of Grade 3 or higher was not observed.
Conclusions
Full-coverage radiotherapy with an optimistic bPFS and rPFS may improve the OS of patients with oligometastatic prostate cancer. Further prospective studies are warranted to confirm the findings of this retrospective analysis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Radiation Oncology, Shanghai Changhai Hospital, the Naval Medical Universit.
Funding
The First Affiliated Hospital of Navy Medical University “234 Subject Climbing Program” (2019YPT004), the First Affiliated Hospital of Naval Medical University “Youth Development Program”(2021JCQNO3).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract